Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

In today's Asking Eric column, R. Eric Thomas responds to someone who is disappointed their friends didn't notice their ...

The incidence of obesity and diabetes is rising in India, the world’s most populous country, which also ranks among the worst ...

Dear Eric: Regarding your response to “What to Say”, who didn’t know how to address a friend’s Ozempic weight loss: ...

The drug is now available for prescription in New Zealand but there are clouds to go along with the silver linings - such as ...

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management ...

As weight-loss drugs like semaglutide and tirzepatide dominate global headlines, a new nationwide survey shows that 87 per cent of Indian adults beli ...

Experts said that the novel combination of a GLP-1 and amylin analogue will help obese patients with and without diabetes ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...

A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...

Once-weekly cagrilintide–semaglutide combination therapy produced unprecedented weight reductions in adults with overweight or obesity, with 60% achieving ≥20% loss and strong cardiometabolic benefits ...